Figure 2

(a) Overall survival in the best supportive care group. Overall survival (OS) was calculated from the date of diagnosis of non-small cell lung cancer to the date of death among patients who received either best supportive care (BSC) alone or BSC after anticancer therapy. Median estimates of OS were as follows: 98.0 days (95% confidence interval [CI], 62.1 to 133.9 days) in the BSC alone group (118 patients, dotted line), and 492.0 days (95% CI, 349.2 to 634.8 days) in the BSC after anticancer therapy group (160 patients, solid line) (p < 0.0001 by the log-rank test). (b) Survival from the start of best supportive care alone in the best supportive care group. Survival was calculated as the duration from the date of diagnosis of non-small cell lung cancer in the best supportive care (BSC) alone group or the date of termination of anticancer therapy in the BSC after anticancer therapy group to the date of death. Median estimates of survival from the start of BSC alone were as follows: 98.0 days (95% CI, 62.1 to 133.9 days) in the BSC alone group (118 patients, dotted line), and 36.0 days (95% CI, 26.7 to 45.3 days) in the BSC after anticancer therapy group (160 patients, solid line) (p < 0.0001 by the log-rank test).